zithromax and Erythema

zithromax has been researched along with Erythema* in 5 studies

Trials

2 trial(s) available for zithromax and Erythema

ArticleYear
[Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis].
    Journal francais d'ophtalmologie, 2010, Volume: 33, Issue:4

    Bacterial conjunctivitis is characterized by hyperemia and discharge of one or both eyes. These clinical signs appear quickly and are contagious. This study compares the clinical efficacy (signs and symptoms) and safety of azithromycin 1.5% eye drops with tobramycin 0.3%.. This was a multicenter, randomized, investigator-masked study including 1,043 patients with purulent bacterial conjunctivitis. Patients received either azithromycin twice daily for 3 days or tobramycin, 1 drop every 2 hours for 2 days, then four times daily for 5 days. The primary variable was clinical cure at the test-of-cure (TOC) visit (D9) on the worst eye. The cure was defined as bulbar conjunctival injection and discharge scores of 0. Clinical signs were evaluated at D0, D3, and D9.. In the azithromycin group 87.8% of patients and in the tobramycin group 89.4% were clinically cured at D9. Clinical cure with azithromycin was not inferior to tobramycin at D9: discharge was absent in 96.3% of patients treated with azithromycin and 95.1% with tobramycin. Azithromycin was well tolerated.. Azithromycin 1.5% for 3 days (six drops) was as effective as tobramycin for 7 days (36 drops). Furthermore, patients on azithromycin presented earlier clinical cure on Day 3 than patients on tobramycin. Azyter, with its convenient dosing (bid for 3 days), is a step forward in the management of purulent bacterial conjunctivitis.

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Child; Child, Preschool; Conjunctiva; Conjunctivitis, Bacterial; Edema; Erythema; Eyelid Diseases; Follow-Up Studies; Humans; Hyperemia; Infant; Infant, Newborn; Middle Aged; Ophthalmic Solutions; Safety; Single-Blind Method; Suppuration; Tobramycin; Treatment Outcome; Young Adult

2010
Toleration of intravenous azithromycin.
    The Annals of pharmacotherapy, 1997, Volume: 31, Issue:9

    To study the toleration of various infusate concentrations of single intravenous doses of azithromycin.. Randomized, double-blind, two-treatment, two-period, crossover.. Clinical pharmacology unit.. Twenty-four healthy men aged 19-41 years.. All subjects were initially randomized to receive single 1-hour intravenous infusions of azithromycin 1 g at infusate concentrations of 1, 2, or 5 mg/mL (n = 6 each) compared with placebo (n = 6). Subjects who were randomized to receive 1 mg/mL concentrations were subsequently administered 5 mg/mL concentrations at least 2 weeks later, those given 2 mg/mL were crossed over to 4 mg/mL, and those in the 5-mg/mL group were crossed over to 1 mg/mL concentrations.. Subjects recorded intravenous infusion toleration using visual analog scales ranging from 0 (no signs or symptoms) to 10 (poor toleration) for erythema, pain, swelling, and tenderness. Vascular Doppler recordings were obtained during and after infusion cephalad to the infusion site.. Infusion site reactions increased in incidence and severity with infusion concentrations of 4 and 5 mg/mL; the most frequent reactions were tenderness and erythema. There were no apparent trends in Doppler readings.. Single doses of azithromycin 1 g at infusate concentrations up to 2 mg/mL were well tolerated when administered over 1 hour to healthy men.

    Topics: Adult; Anti-Bacterial Agents; Azithromycin; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Erythema; Humans; Infusions, Intravenous; Male; Pain Measurement

1997

Other Studies

3 other study(ies) available for zithromax and Erythema

ArticleYear
Erythema annulare centrifugum triggered by COVID-19 vaccination with complete response to prolonged azithromycin treatment.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2023, Volume: 37, Issue:3

    Topics: Azithromycin; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Erythema; Humans; Skin Diseases, Genetic; Vaccination

2023
An observational study of the efficacy of azithromycin in erythema annulare centrifugum.
    Clinical and experimental dermatology, 2018, Volume: 43, Issue:3

    Erythema annulare centrifugum (EAC) is a form of figurate erythema consequent to a cutaneous hypersensitivity reaction to an underlying agent. In the present study, we aimed to assess the role of oral azithromycin in cases of idiopathic EAC. We performed an open trial of azithromycin in 10 patients with idiopathic EAC. Histopathological examination of biopsies was performed to exclude any alternative diagnosis and to assess the depth of the infiltrate. Patients were administered oral azithromycin 250 mg once daily until clinical resolution of the disease, and followed up regularly to monitor for possible relapse. Histopathological examination of the 10 biopsies revealed superficial pattern in 3, deep pattern in 2 and mixed pattern in the remaining 5. Of the 10 patients, 8 responded to azithromycin 250 mg, with no relapse during follow-up. Oral azithromycin might be a promising therapy in cases of idiopathic EAC. Cases with a superficial pattern respond earlier than cases with a deep pattern.

    Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Azithromycin; Biopsy; Child; Erythema; Female; Humans; Male; Skin Diseases, Genetic; Young Adult

2018
Oral azithromycin for treatment of intractable rosacea.
    Journal of Korean medical science, 2011, Volume: 26, Issue:5

    Rosacea is a common chronic cutaneous disorder that primarily occurs on the convex surfaces of the central face and is often characterized by exacerbations and remissions. A case of a 52-yr-old woman visited our clinic in February 2008 complaining typical features of rosacea including multiple pinhead to rice-sized erythematous papules. We applied various conventional treatments including topical benzoyl peroxide and metronidazole as well as oral metronidazole, isotretinoin, and doxycycline. The lesions were not controlled but were rather aggravated by complications from these treatments. Therefore, we prescribed oral azithromycin, which has anti-inflammatory effects and reduces reactive oxygen species. Ten weeks after the administration of oral azithromycin, 500 mg per day for 2 weeks, the lesions had mostly disappeared and no specific side effects related to the azithromycin were noted. Oral azithromycin dosing 500 mg/day for 2 weeks is effective for treatment of intractable rosacea.

    Topics: Administration, Oral; Azithromycin; Erythema; Female; Humans; Middle Aged; Reactive Oxygen Species; Rosacea; Skin Diseases

2011